朱伯达,韩鹏,马炳琦,赵帅,王嘉仪,曹家豪,王紫薇,邹一鸣,胡文涛,魏志宏,汪钦,李成祥,廉坤

• 1:中国人民解放军空军军医大学第一附属医院心内科
• 2:空军航空大学初级飞行训练基地
• 3:中国人民解放军联勤保障部队第九八一医院心血管内科
• 4:中国人民解放军联勤保障部队九六五医院心血管内科

摘要(Abstract)：

目的 观察冠状动脉粥样硬化性心脏病（CHD）患者血浆致动脉粥样硬化指数（AIP）与冠状动脉慢性完全闭塞（CTO）病变的相关性。方法 连续收集2009年11月至2020年7月于中国人民解放军空军军医大学第一附属医院初诊的CHD患者2 754例，评估患者冠状动脉病变狭窄严重程度，并将其分为非CTO组（1 904例）和CTO组（850例）。记录两组患者住院期间的基线资料并计算AIP和Gensini评分（GS）。使用受试者工作特征（ROC）曲线计算AIP的曲线下面积，得到CTO病变诊断的截断值；并使用单因素与多因素分析方法对CTO病变的危险因素进行分析。结果 用ROC曲线测得AIP的曲线下面积为0.580(95%CI 0.556～0.604,P<0.001)，敏感度为0.612，特异度为0.528。CTO病变诊断的截断值为AIP=0.140。经过多因素Logistic回归分析后发现，总胆固醇水平升高（OR 1.200,95%CI 1.007～1.338,P=0.001）、低密度脂蛋白胆固醇水平升高（OR1.323,95%CI 1.158～1.511,P<0.001）、AIP>0.140(OR 1.540,95%CI 1.257～1.887,P<0.001)是CTO病变的危险因素。结论 AIP升高与CTO病变有相关性，其对于CTO病变有较好的预测价值。

关键词(KeyWords)： 冠状动脉粥样硬化性心脏病;血浆致动脉粥样硬化指数;冠状动脉慢性完全闭塞;Gensini积分

Abstract:

Keywords:

基金项目(Foundation): 陕西省重点研发计划项目（2018SF-153）;; 白求恩-默克糖尿病研究基金项目（G2017044）;; 西京医院临床新技术新业务项目（XJGX15Y39）;; 西安市科技计划项目[20YXYJ0003(4)]

作者(Author): 朱伯达,韩鹏,马炳琦,赵帅,王嘉仪,曹家豪,王紫薇,邹一鸣,胡文涛,魏志宏,汪钦,李成祥,廉坤

参考文献(References)：

• [1] Hussain I, Patni N, Garg A,et al. Lipodystrophies,dyslipidaemias and atherosclerotic cardiovascular disease[J].Pathology, 2019, 51(2):202-212.
• [2] Fernández-Macías JC, Ochoa-Martínez AC, Varela-Silva JA,et al. Atherogenic index of plasma:novel predictive biomarker for cardiovascular illnesses[J]. Arch Med Res, 2019,50(5):285-294.
• [3] Cai G, Shi G, Xue S, et al. The atherogenic index of plasma is a strong and independent predictor for coronary artery disease in the Chinese Han population[J]. Medicine(Baltimore),2017,96(37):e8058.
• [4] Bhatnagar UB, Shrestha A, Petrasko M,et al. Current evidence and rationale of percutaneous therapy for chronic total coronary occlusions[J]. Curr Probl Cardiol, 2019,44(12):100412.
• [5] Stojkovic S, Juricic S, Dobric M, et al. Improved propensityscore matched long-term clinical outcomes in patients with successful percutaneous coronary interventions of coronary chronic total occlusion[J]. Int Heart J, 2018,59(4):719-726.
• [6]杜旭，王永，吴天兵，等.冠状动脉慢性完全闭塞性病变逆向介入治疗失败的发生率和预测因素研究[J].中国动脉硬化杂志，2021,29(10):891-895.
• [7] Cai G, Liu W, Lv S, et al. Gender-specifi c associations between atherogenic index of plasma and the presence and severity of acute coronary syndrome in very young adults:a hospital-based observational study[J]. Lipids Health Dis, 2019,18(1):99.
• [8] Ybarra LF, Rinfret S, Brilakis ES, et al. Definitions and clinical trial design principles for coronary artery chronic total occlusion therapies:CTO-ARC consensus recommendations[J].Circulation, 2021, 143(5):479-500.
• [9] Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease[J]. Am J Cardiol,1983, 51(3):606.
• [10]马丽媛，王增武，樊静，等.《中国心血管健康与疾病报告2021》概要[J].中国介入心脏病学杂志，2022,30(7):481-496.
• [11] R?munddal T, Hoebers LP, Henriques JP, et al. Chronic total occlusions in sweden--a report from the swedish coronary angiography and angioplasty registry(SCAAR)[J].PLoS One, 2014,9(8):e103850.
• [12] Shuvy M, Qiu F, Chee-A-Tow A, et al. Management of chronic total coronary occlusion in stable ischemic heart disease by percutaneous coronary intervention versus coronary artery bypass grafting versus medical therapy[J]. Am J Cardiol,2017,120(5):759-764.
• [13] Christof ferson RD, Lehmann KG, Martin GV,et al. Ef fect of chronic total coronary occlusion on treatment strategy[J].Am J Cardiol, 2005,95(9):1088-1091.
• [14] Kahn JK. Angiographic suitability for catheter revascularization of total coronary occlusions in patients from a community hospital setting[J]. Am Heart J, 1993. 126(3 Pt 1):561-564.
• [15] Allahwala UK, Ekmejian A, Mughal N, et al. Impact of coronary artery bypass grafting(CABG)on coronary collaterals in patients with a chronic total occlusion(CTO)[J]. Int J Cardiovasc Imaging, 2021,37(12):3373-3380.
• [16]安明春，杨旭明，赵江峰，等.开通冠状动脉CTO对冠心病患者生活质量的影响分析[J].中国循证心血管医学杂志，2021,13(7):876-881.
• [17] Liu T, Liu J, Wu Z, et al. Predictive value of the atherogenic index of plasma for chronic total occlusion before coronary angiography[J]. Clin Cardiol, 2021,44(4):518-525.
• [18] Robinson JG. Are you targeting non-high-density lipoprotein cholesterol[J]? J Am Coll Cardiol, 2009, 55(1):42-44.
• [19] Generoso G, Janovsky CCPS, Bittencourt MS.Triglycerides and triglyceride-rich lipoproteins in the development and progression of atherosclerosis[J]. Curr Opin Endocrinol Diabetes Obes, 2019, 26(2):109-116.
• [20] Tada H, Nohara A, Kawashiri MA.Serum triglycerides and atherosclerotic cardiovascular disease:insights from clinical and genetic studies[J]. Nutrients, 2018, 10(11):1789.
• [21] Toth PP. Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease[J]. Vasc Health Risk Manag, 2016,12:171-183.
• [22] Sarhadi S, Ganjali S, Pirro M,et al. The role of high-density lipoproteins in antitumor drug delivery[J]. IUBMB Life,2019, 71(10):1442-1452.
• [23] Wong NKP, Nicholls SJ, Tan JTM,et al. The role of highdensity lipoproteins in diabetes and its vascular complications[J].Int J Mol Sci, 2018,19(6):1680.
• [24] PotìF, Simoni M, Nofer JR. Atheroprotective role of highdensity lipoprotein(HDL)-associated sphingosine-1-phosphate(S1P)[J]. Cardiovasc Res, 2014, 103(3):395-404.
• [25] Wang L, Chen F, Xiaoqi C,et al. Atherogenic index of plasma is an independent risk factor for coronary artery disease and a higher SYNTAX score[J]. Angiology, 2021, 72(2):181-186.
• [26] Nam JS, Kim MK, Nam JY, et al. Association between atherogenic index of plasma and coronary artery calcification progression in Korean adults[J]. Lipids Health Dis, 2020,19(1):157.
• [27] Guelker JE, Bufe A, Blockhaus C, et al. The atherogenic index of plasma and its impact on recanalization of chronic total occlusion[J]. Cardiol J, 2020, 27(6):756-761.